Advertisement
Advertisement
U.S. markets close in 6 hours 21 minutes
Advertisement
Advertisement
Advertisement
Advertisement

American CryoStem Corporation (CRYO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2623+0.0023 (+0.88%)
As of 02:51PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2600
Open0.2601
Bid0.1050 x 5000
Ask1.5000 x 500
Day's Range0.2601 - 0.2623
52 Week Range0.1600 - 1.1700
Volume2,648
Avg. Volume19,221
Market Cap11.461M
Beta (5Y Monthly)-0.58
PE Ratio (TTM)N/A
EPS (TTM)-0.0710
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CRYO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AMERICAN CRYOSTEM CORPORATION
    Technical Assessment: Bearish in the Intermediate-TermCommodities continue to get shellacked, Treasury yields across the curve are still falling, people are starting to suggest that the Federal Reserve won't have to tighten as much as many thought just a month or two ago, recession fears (or worries that we are already in one) are rising quickly, EPS season is almost upon us (with many believing 2022 numbers are far too high), crypto remains in the dumpster, and the horrendous invasion of Ukraine never ends.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • ACCESSWIRE

    American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)

    EATONTOWN, NJ / ACCESSWIRE / March 4, 2022 / American CryoStem Corporation (OTC PINK:CRYO) a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and cellular therapies, announced today that it has reached the midway point of its ATCell™ autologous mesenchymal stem cell therapy for Phase I Clinical Trial for Post-concussion syndrome (PCS).The Company's autologous mesenchymal stem cell infusion therapy Investigational Drug is part of a single cent

  • ACCESSWIRE

    American CryoStem Announces Completion of Patient Recruitment for its Post-Concussion Syndrome (PCS) ATCELL(TM) Phase I Clinical Trial

    EATONTOWN, NJ / ACCESSWIRE / December 22, 2021 / American CryoStem Corporation (OTC PINK:CRYO) a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced today that its clinical study team has completed recruiting subjects for its Investigational New Drug (IND) Phase I Clinical Trial for Post-concussion syndrome. The singe site, multi-dosage blinded study is being conducted by BioSolutions Clinical Research Center, LLC.

  • ACCESSWIRE

    American CryoStem Completes Clinical Protocol Design for Long COVID Study

    EATONTOWN, NJ / ACCESSWIRE / November 30, 2021 /American CryoStem Corporation (OTC PINK:CRYO), a leading clinical-stage biotechnology developer of adipose-derived stem cell therapies today announced completion of its Phase I clinical protocol design for the treatment of Long COVID. American CryoStem anticipates that the protocol will be filed as an FDA Phase I IND in cooperation with a major US medical center in Q-1, 2022.

Advertisement
Advertisement